Unlocking Hidden Biological Signals for Human Longevity
MassClaw is an AI-powered Proteomics Intelligence Platform transforming LC-MS data into deep biological discoveries, early diagnostics, and the future of healthy human lifespan.
The Three Stages of Human Life
Reimagining time, health, and human potential.
Time & Curiosity
When we are young, we often have time, energy, curiosity, and dreams, but little money. We exchange our time for opportunities and income.
Resources & Pressure
As we grow older, we gain greater resources and responsibilities, yet find ourselves trapped between careers, obligations, and limited time.
The Healthspan Gap
By retirement, we finally possess the time we once wished for, but often discover that our health and energy are no longer what they once were.
"As a result, many people never get the chance to fully explore the world, pursue their dreams, or become the person they hoped to be."
Our Mission: Bridging the gap between lifespan and healthspan through proteomics intelligence.
The Hidden Future of Human Health
Modern proteomics technologies generate unprecedented volumes of biological data.
Yet much of the biological intelligence that drives disease, aging, and longevity remains undiscovered.
We believe the next breakthrough in human healthspan may already exist within today's data.
Proteins Are Where Biology Becomes Medicine
Genes provide biological instructions.
Proteins determine how cells function, how diseases develop, and how therapies work.
Most longevity biomarkers and therapeutic targets are found at the protein level.
Genes tell us what could happen.
Proteins tell us what is happening.
AI-Powered Proteomics Intelligence Platform
MassClaw combines artificial intelligence, advanced analytics, and proteomics to help researchers transform complex LC-MS data into actionable discoveries for human longevity.
Biomarkers
Early diagnostic signatures for complex pathologies.
Drug Targets
Actionable protein nodes for targeted therapeutics.
Disease Insights
Mechanistic pathways unravelling disease progression.
Longevity Research
Proteomic signatures of healthy aging and resilience.
LC-MS generates the data. MassClaw generates the intelligence.
Our Co-Founding Team
GUO Weiheng
CTO
- PhD in Biomedical Science
- Bioinformatics & AI in Drug Discovery
- Published in top-tier medical journal: The Lancet R.H.
- Member of Chinese Chemical Society & HK Mass Spectrometry Society
LIAO Bin
CAIO
- PhD in Biomedical Science
- Applied AI Agent Development in Proteomics
- First-author publication on ATAC-seq technology
- Member of Chinese Chemical Society & HK Mass Spectrometry Society
YUE Hin Lok
CEO-CBO
- BSc in Chemistry
- Commercial Development
- Expertise: LC-MS-based Clinical and Translational Proteomics
- Member of HK Mass Spectrometry Society
Prof. ZHANG Liang
Scientific Advisor
- PI of Zhang Liang's Lab
- 4300+ Citations (Scopus, h-index 31)
- Stanford's top 2% most highly cited scientists
- Project Coordinator, directing HK$10M+ Research Projects
- Expert in High-Performance Mass Spectrometry & Proteomics
- Chairperson of the HK Society of Mass Spectrometry (HKSMS)
Global Impact
Scientific Impact
Accelerating biomarker discovery and biological research.
Economic Impact
Improving research efficiency and increasing dataset value.
Societal Impact
Advancing precision medicine, healthspan extension, and healthy aging.
The Next Breakthrough in Medicine May Already Exist Within Today's Data
Hidden Signals. Better Medicine. Longer, Healthier Lives.